The sudden resignation of Yu Tao, the long-standing Board Secretary of Wantai Biological, marks a symbolic turning point for a company that was once the crown jewel of China’s domestic vaccine industry. After nearly two decades with the firm, Yu’s departure comes despite a lucrative compensation package exceeding 1.4 million yuan and personal equity holdings valued at over 14 million yuan. His exit, officially attributed to personal family reasons, coincides with a period of unprecedented financial turbulence for the 50-billion-yuan biopharmaceutical giant.
Wantai’s financial trajectory has shifted from a pandemic-era windfall to a projected net loss of up to 410 million yuan for 2025. This downturn is primarily fueled by a collapse in the profitability of its signature 2-valent HPV vaccine, which once enjoyed a near-monopoly as the first domestic alternative to expensive imports. As multinational competitors like Merck (MSD) expanded the age range for their superior 9-valent vaccines, Wantai’s flagship product was relegated to a low-margin commodity, forcing the company to write off hundreds of millions in near-expiry inventory.
The domestic market has devolved into a brutal 'price war' that serves as a cautionary tale for China’s high-tech manufacturing sectors. In a desperate bid to secure government procurement contracts, prices for the 2-valent HPV vaccine have plummeted by nearly 90%, crashing from over 300 yuan per dose to less than 30 yuan in just three years. This race to the bottom has effectively evaporated the profit margins that previously funded the company’s ambitious research and development pipelines.
To survive, Wantai is now pivoting toward aggressive international expansion and the accelerated development of its own 9-valent candidate. While the company reported a surge in overseas revenue for 2025, with its products entering over 20 countries, the global landscape remains crowded. The veteran board secretary’s exit may suggest that for the insiders who built Wantai’s initial success, the arduous climb back to profitability in a commoditized market is a challenge they are no longer willing to lead.